Difference between revisions of "Tositumomab and I-131 (Bexxar)"
(Created page with "==General information== Class/mechanism: <ref name="insert">[http://us.gsk.com/products/assets/us_bexxar.pdf Tositumomab & I-131 (Bexxar) package insert]</ref><ref>[http://hemonc...") |
|||
| Line 1: | Line 1: | ||
| + | Also known as tositumomab and I-131 tositumomab, or tositumomab and iodine-131 tositumomab. | ||
| + | |||
==General information== | ==General information== | ||
| − | Class/mechanism: <ref name="insert">[http://us.gsk.com/products/assets/us_bexxar.pdf Tositumomab | + | Class/mechanism: Radioimmunotherapy; treatment regimen that includes two separate steps: first, a dosimetric dose with an anti-CD20 antibody (tositumomab) alone, and secondly a therapeutic dose with tositumomab bound to a radioactive isotope (iodone-131, I-131). Tositumomab binds to the extracellular domain of the CD20 molecule expressed on B-cells and may induce complement-dependent and/or antibody-dependent cell-mediated cytotoxicity. The I-131 that is bound to tositumomab emits ionizing radiation, leading to cell death.<ref name="insert">[http://us.gsk.com/products/assets/us_bexxar.pdf Tositumomab and I-131 (Bexxar) package insert]</ref><ref>[http://hemonc.org/docs/packageinsert/tositumomabI131.pdf Tositumomab and I-131 (Bexxar) package insert (locally hosted backup)]</ref> |
| − | <br>Route: | + | <br>Route: IV |
| − | <br>Extravasation: | + | <br>Extravasation: no information |
| − | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the package insert<ref name="insert"></ref>. | + | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the package insert<ref name="insert"></ref>. |
==Patient drug information== | ==Patient drug information== | ||
| − | *[http://chemocare.com/bio/tositumomab.asp Tositumomab | + | *[http://chemocare.com/bio/tositumomab.asp Tositumomab and I-131 (Bexxar) patient drug information (Chemocare)]<ref>[http://chemocare.com/bio/tositumomab.asp Tositumomab and I-131 (Bexxar) patient drug information (Chemocare)]</ref> |
| − | *[http://www.uptodate.com/contents/ | + | *[http://www.uptodate.com/contents/tositumomab-radioconjugate-patient-drug-information Tositumomab and I-131 (Bexxar) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/tositumomab-radioconjugate-patient-drug-information Tositumomab and I-131 (Bexxar) patient drug information (UpToDate)]</ref> |
==References== | ==References== | ||
<references/> | <references/> | ||
Revision as of 06:53, 25 February 2012
Also known as tositumomab and I-131 tositumomab, or tositumomab and iodine-131 tositumomab.
General information
Class/mechanism: Radioimmunotherapy; treatment regimen that includes two separate steps: first, a dosimetric dose with an anti-CD20 antibody (tositumomab) alone, and secondly a therapeutic dose with tositumomab bound to a radioactive isotope (iodone-131, I-131). Tositumomab binds to the extracellular domain of the CD20 molecule expressed on B-cells and may induce complement-dependent and/or antibody-dependent cell-mediated cytotoxicity. The I-131 that is bound to tositumomab emits ionizing radiation, leading to cell death.[1][2]
Route: IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the package insert[1].
Patient drug information
- Tositumomab and I-131 (Bexxar) patient drug information (Chemocare)[3]
- Tositumomab and I-131 (Bexxar) patient drug information (UpToDate)[4]